|
業務類別
|
Biotechnology |
|
業務概覽
|
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancersand solid tumors. |
| 公司地址
| 5858 Horton Street, Suite 370, Emeryville, CA, USA, 94608 |
| 電話號碼
| +1 510 318-9098 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.estrellabio.com |
| 員工數量
| 3 |
| Ms. Qian Yang |
Chief Operating Officer |
-- |
05/10/2023 |
| Dr. Cheng Liu, PhD |
Chief Executive Officer, President and Director |
-- |
18/03/2026 |
| Mr. Jiandong Xu |
Chief Financial Officer and Principal Accounting Officer |
-- |
18/03/2026 |
|
|
| Ms. Hong Zhang |
Chairman of the Board |
18/03/2026 |
| Mr. Dengyao Jia |
Director |
18/03/2026 |
| Mr. Jia Dengyao |
Director |
26/09/2025 |
| Mr. Fan Wu |
Independent Director |
18/03/2026 |
| Dr. Marsha Roberts |
Independent Director |
18/03/2026 |
| Ms. Xuejun Janelle Wu |
Independent Director |
18/03/2026 |
| Dr. Cheng Liu, PhD |
Chief Executive Officer, President and Director |
18/03/2026 |
| Ms. Pei Xu |
Independent Director |
18/03/2026 |
|
|
|
|
